Combined effects of bucillamine and etanercept on a rat type II collagen-induced arthritis model

Abstract

The combined effects of bucillamine (Buc) and etanercept (ETN) on a rat model of type II collagen (CII)-induced arthritis (CIA) after treatment onset were investigated. In the combination treatment, rats received Buc 30 mg/kg orally administered once daily from the onset of arthritis or from 4 days after the onset of arthritis and ETN 0.3 mg/kg subcutaneously administered once on the day of onset. The effects of monotherapy with Buc and ETN, respectively, and of Buc + ETN combination therapy on the resulting polyarthritis were evaluated by histopathological analyses and measurements of hindpaw volumes, serum anti-collagen antibody and immunoglobulin levels, and cytokine levels. The Buc + ETN therapeutic combination reduced hindpaw swelling, synovial proliferation, bone destruction, new bone formation, and inflammatory cell infiltration in CIA. Montherapy with Buc showed a tendency to ameliorate these symptoms, while monotherapy with ETN reduced hindpaw swelling at 4 days after administration but did not maintain treatment efficacy toward the end of the experimental period. Histopathological findings did not reveal any efficacy of the ETN therapy. ETN alone increased the serum immunoglobulin levels, while its combination with Buc reduced these levels. Similar results were obtained for serum anti-CII antibody titers. The Buc + ETN combination treatment also reduced serum interleuking (IL)-1alpha and granulocyte macrophage colony-stimulating factor and tended to reduce serum IL-1beta and IL-6 levels. These results suggest that a combination therapy of Buc and ETN may be effective for the treatment of rheumatoid arthritis (RA).

Functionalized STAT1 siRNA Nanoparticles Regress Rheumatoid Arthritis in A Mouse Model

“…We initiated treat ment on day 35, a time at which most mice had developed arthritis. This is in contrast to the majority of studies in which the drug being stud ied is administered at or before the initiation of the disease [25][26][27][28][29][30]. If one uses TNFa blockade as an example, treatment at the time of disease initiation results in a profound block in disease.…”

Possibilities for preventive treatment in rheumatoid arthritis? Lessons from experimental animal models of arthritis: a systematic literature review and meta-analysis

“…DMARDs tested were leflunomide (one experiment),32 methotrexate (four experiments),33–35 anti-tumour necrosis factor (TNF) (two experiments)36 and anti-interleukin (IL)1 (two experiments) 37. A meta-analysis of these studies demonstrated that prearthritis intervention is associated with a reduction of arthritis severity in animal models of arthritis (p=0.005).…”

Etanercept ameliorates inflammation and pain in a novel mono-arthritic multi-flare model of streptococcal cell wall induced arthritis

“…To further characterize our model, we profiled a panel of therapeutic agents such as, etanercept, dexamethasone and buprenorphine. We selected these agents based on their established efficacy in other preclinical models of arthritis [ 55 – 57 ]. The specific doses used for each drug in these studies were selected based on multiple dose response studies conducted internally (data not shown).…”